Výsledky vyhledávání - "Maja, de Jonge"

Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, Basket Study

Autor: Matthew G. Krebs, Jean-Pierre Delord, Thomas R. Jeffry Evans, Maja De Jonge, Sang-We Kim, Marie Meurer, Sophie Postel-Vinay, Jong-Seok Lee, Helen K. Angell, Vidalba Rocher-Ros, Kassondra Meyer, Mei-Lin Ah-See, Pia Herbolsheimer, Zhongwu Lai, Ana Nunes, Susan M. Domchek

Publikováno v: Krebs, M G, Delord, J-P, Jeffry Evans, T R, De Jonge, M, Kim, S-W, Meurer, M, Postel-Vinay, S, Lee, J-S, Angell, H K, Rocher-Ros, V, Meyer, K, Ah-See, M-L, Herbolsheimer, P, Lai, Z, Nunes, A & Domchek, S M 2023, ' Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, Basket Study ', Lung Cancer, vol. 180, 107216 . https://doi.org/10.1016/j.lungcan.2023.107216
Lung Cancer, 180:107216. Elsevier Ireland Ltd

Introduction: Preclinical studies have demonstrated increased efficacy with combined DNA damage response inhibition and immune checkpoint blockade compared with either alone. We assessed olaparib in combination with durvalumab in patients with relaps

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f55b6a72887c16967c05c789e2f26d5
https://doi.org/10.1016/j.lungcan.2023.107216

Zobrazit plný text záznamu

Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma

Publikováno v: Neuro-Oncology Advances, 4(1):vdac146. Oxford University Press
Scientia

Background Standard-of-care treatment for newly diagnosed glioblastoma (ndGBM), consisting of surgery followed by radiotherapy (RT) and temozolomide (TMZ), has improved outcomes compared with RT alone; however, prognosis remains poor. Trotabresib, a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f12eaafe59322f3b7697cccec754b55
https://pure.eur.nl/en/publications/8c7f43ea-d16a-4ab8-9cbc-301f4b9a0462

Zobrazit plný text záznamu

First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours

Autor: Patrick Schöffski, Ahmad Awada, Anne-Marie de la Bigne, Zakia Felloussi, Mike Burbridge, Frederique Cantero, Riccardo Colombo, Sara Maruzzelli, Katia Ammattatelli, Maja de Jonge, Philippe Aftimos, Herlinde Dumez, Stefan Sleijfer

Publikováno v: European Journal of Cancer, 169, 135-145. Elsevier Ltd.

BACKGROUND: S81694 is an inhibitor of monopolar spindle 1 kinase, a target expressed in proliferating cells. CL1-81694-001 was the first-in-human study aiming at identifying a safe dosing schedule in solid tumour patients. PATIENTS AND METHODS: This

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5105915d663ef0244a4dda06eebfbd04
https://lirias.kuleuven.be/handle/20.500.12942/697837

Zobrazit plný text záznamu

Akademický článek

Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material.

Autor: Wendy W J de Leng, Christa G Gadellaa-van Hooijdonk, Françoise A S Barendregt-Smouter, Marco J Koudijs, Ies Nijman, John W J Hinrichs, Edwin Cuppen, Stef van Lieshout, Robert D Loberg, Maja de Jonge, Emile E Voest, Roel A de Weger, Neeltje Steeghs, Marlies H G Langenberg, Stefan Sleijfer, Stefan M Willems, Martijn P Lolkema

Publikováno v: PLoS ONE, Vol 11, Iss 2, p e0149405 (2016)

Targeted Next Generation Sequencing (NGS) offers a way to implement testing of multiple genetic aberrations in diagnostic pathology practice, which is necessary for personalized cancer treatment. However, no standards regarding input material have be

Externí odkaz: https://doaj.org/article/d24f1077607043a59bda3a036165608a

Zobrazit plný text záznamu

Abstract CT514: A phase I, open-label, dose-escalation study investigating a low-density lipoprotein receptor-related protein (LRP) 5/6 inhibitor, BI 905677, in patients with advanced solid tumors

Autor: Elena Élez, Heinz-Josef Lenz, Maja de Jonge, Rona Yaeger, Toshihiko Doi, Linda Pronk, Michael Teufel, Kristell Marzin, Josep Tabernero

Publikováno v: Cancer Research. 82:CT514-CT514

Background: Ligand-dependent Wnt signaling, mediated by LRP5/6, is highly activated in a subset of solid tumors. Activation leads to accumulation of intracellular β-catenin and expression of β-catenin-dependent genes that promote cancer cell prolif

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::26cefd192958d185611c656e333873f3
https://doi.org/10.1158/1538-7445.am2022-ct514

Zobrazit plný text záznamu

Capmatinib in

Publikováno v: The New England journal of medicine. 383(10)

Among patients with non-small-cell lung cancer (NSCLC),We conducted a multiple-cohort, phase 2 study evaluating capmatinib in patients withA total of 364 patients were assigned to the cohorts. Among patients with NSCLC with aCapmatinib showed substan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::776107e1d455f68ddd285239ab211d1b
https://pubmed.ncbi.nlm.nih.gov/32877583

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání